Testing a new drug for HER2-positive advanced solid cancers
Part of Cancer clinical trials.
This Phase 1 trial tests D3L-001 alone in people with HER2-positive advanced solid tumors. It’s mainly looking to see how the drug works and how safe it is in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed HER2-positive cancer from an approved test (like IHC, ISH, or NGS).
- Your energy/performance is good, rated as ECOG 0 or 1.
- Your heart pumping strength is normal (left ventricular ejection fraction at least 50%) on an approved heart scan.
- Your blood and other organs can handle the study treatment (meeting lab “organ/marrow function” requirements).
- You have not taken anti-CD47 or SIRPα medicines before.
- You can meet medication timing rules (including proper washout from prior treatments) and may need to stop certain non-completed immune-suppressing medicines 14 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, D3L-002, for people with advanced solid tumors that have stopped responding to at least one prior treatment or have no standard options. The goal is to see if it can help shrink or control the cancer.
This Phase 1 trial tests a combination of medicines (including DS-1103a) for people with advanced, hard-to-remove (unresectable) or metastatic solid tumors that have HER2 changes. Because it’s an early safety/dose study, it mainly aims to find the right dose and see how the tumor responds.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This trial tests a new drug, CAN016, for people with advanced solid tumors that have HER2 expression or a HER2 gene change. You may qualify if your cancer has gotten worse after trying other HER2-targeted treatments.
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
This trial tests two experimental drugs, SI-B003 and BL-B01D1 plus SI-B003, for people with HER2-negative breast cancer that has spread or cannot be removed by surgery. It is for those who have tried standard treatments or cannot have them.
Hear when a new HER-2 Positive Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.